Ryan Cohlhepp

CIK: 0002034665

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)29 (65.9%)

Position reduction

Option Exercises (M)14 (31.8%)

Derivative conversions

Awards (A)1 (2.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BCAX

Bicara Therapeutics Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (44 total)

BCAX
Bicara Therapeutics Inc.
Sep 8, 2026
Sale(S)
Direct
3.4K shares at avg. $23.43$81K
BCAX
Bicara Therapeutics Inc.
Sep 8, 2026
Sale(S)
Direct
14.1K shares at avg. $22.77$320K
BCAX
Bicara Therapeutics Inc.
Sep 8, 2026
Exercise(M)
Direct
17.5K shares at avg. $3.79$66K
BCAX
Bicara Therapeutics Inc.
Aug 10, 2026
Sale(S)
Direct
18.8K shares at avg. $27.98$525K
BCAX
Bicara Therapeutics Inc.
Aug 10, 2026
Exercise(M)
Direct
18.8K shares at avg. $3.79$71K
BCAX
Bicara Therapeutics Inc.
Jul 9, 2026
Sale(S)
Direct
536 shares at avg. $29.00$16K
BCAX
Bicara Therapeutics Inc.
Jul 8, 2026
Sale(S)
Direct
22.8K shares at avg. $28.76$657K
BCAX
Bicara Therapeutics Inc.
Jul 8, 2026
Sale(S)
Direct
1.1K shares at avg. $30.35$33K
BCAX
Bicara Therapeutics Inc.
Jul 8, 2026
Sale(S)
Direct
4.3K shares at avg. $29.80$128K
BCAX
Bicara Therapeutics Inc.
Jul 8, 2026
Exercise(M)
Direct
18.8K shares at avg. $3.79$71K
BCAX
Bicara Therapeutics Inc.
May 15, 2026
Sale(S)
Direct
8K shares at avg. $20.29$162K
BCAX
Bicara Therapeutics Inc.
May 15, 2026
Exercise(M)
Direct
8K shares at avg. $3.79$30K
BCAX
Bicara Therapeutics Inc.
May 15, 2026
Sale(S)
Direct
4.5K shares at avg. $20.29$91K
BCAX
Bicara Therapeutics Inc.
Apr 15, 2026
Sale(S)
Direct
4.5K shares at avg. $23.01$104K
BCAX
Bicara Therapeutics Inc.
Apr 15, 2026
Exercise(M)
Direct
8K shares at avg. $3.79$30K
BCAX
Bicara Therapeutics Inc.
Apr 15, 2026
Sale(S)
Direct
8K shares at avg. $23.01$184K
BCAX
Bicara Therapeutics Inc.
Mar 16, 2026
Exercise(M)
Direct
8K shares at avg. $3.79$30K
BCAX
Bicara Therapeutics Inc.
Mar 16, 2026
Sale(S)
Direct
8K shares at avg. $19.66$157K
BCAX
Bicara Therapeutics Inc.
Mar 16, 2026
Sale(S)
Direct
4.5K shares at avg. $19.66$88K
BCAX
Bicara Therapeutics Inc.
Mar 3, 2026
Exercise(M)
Direct
12.9K shares at avg. $3.79$49K
BCAX
Bicara Therapeutics Inc.
Mar 3, 2026
Sale(S)
Direct
12.9K shares at avg. $18.16$234K
BCAX
Bicara Therapeutics Inc.
Mar 3, 2026
Sale(S)
Direct
4.5K shares at avg. $18.16$82K
BCAX
Bicara Therapeutics Inc.
Feb 25, 2026
Sale(S)
Direct
523 shares at avg. $18.04$9K
BCAX
Bicara Therapeutics Inc.
Feb 25, 2026
Exercise(M)
Direct
3.1K shares at avg. $3.79$12K
BCAX
Bicara Therapeutics Inc.
Feb 25, 2026
Sale(S)
Direct
3.1K shares at avg. $18.04$56K

		Type	Shares	Price		Ownership
Sep 8, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	3,442	$23.43	$80,663	Direct
Sep 8, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	14,058	$22.77	$320,053	Direct
Sep 8, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	17,500	$3.79	$66,322	Direct
Aug 10, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	18,750	$27.98	$524,533	Direct
Aug 10, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	18,750	$3.79	$71,059	Direct
Jul 9, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	536	$29.00	$15,544	Direct
Jul 8, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	22,833	$28.76	$656,652	Direct
Jul 8, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	1,075	$30.35	$32,632	Direct
Jul 8, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	4,306	$29.80	$128,302	Direct
Jul 8, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	18,750	$3.79	$71,059	Direct
May 15, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	8,000	$20.29	$162,335	Direct
May 15, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	8,000	$3.79	$30,318	Direct
May 15, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	4,500	$20.29	$91,314	Direct
Apr 15, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	4,500	$23.01	$103,533	Direct
Apr 15, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	8,000	$3.79	$30,318	Direct
Apr 15, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	8,000	$23.01	$184,058	Direct
Mar 16, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	8,000	$3.79	$30,318	Direct
Mar 16, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	8,000	$19.66	$157,257	Direct
Mar 16, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	4,500	$19.66	$88,457	Direct
Mar 3, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	12,892	$3.79	$48,858	Direct
Mar 3, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	12,892	$18.16	$234,159	Direct
Mar 3, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	4,500	$18.16	$81,734	Direct
Feb 25, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	523	$18.04	$9,435	Direct
Feb 25, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	3,108	$3.79	$11,779	Direct
Feb 25, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	3,108	$18.04	$56,067	Direct

1-25 of 44 transactions

About Cohlhepp Ryan

Cohlhepp Ryan (SEC CIK 0002034665) files insider reports with the SEC as President, COO & Interim CEO of Bicara Therapeutics Inc. (BCAX).

Signal8 holds 17 ownership filings by Cohlhepp Ryan (1 Form 3, 16 Form 4), filed between Sep 12, 2024 and Sep 10, 2026. Those filings report 44 transactions, from Oct 6, 2025 to Sep 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cohlhepp Ryan's filings is in BOSTON, MA.

Recent filings by Cohlhepp Ryan

Sep 8, 2026: Open-market sales of BCAX shares (2 lines, Form 4, code S).
Sep 8, 2026: Option exercise of BCAX shares (Form 4, code M).
Aug 10, 2026: Open-market sale of BCAX shares (Form 4, code S).
Aug 10, 2026: Option exercise of BCAX shares (Form 4, code M).
Jul 9, 2026: Open-market sale of BCAX shares (Form 4, code S).

Other insiders filing for Bicara Therapeutics Inc. (BCAX)

Larson Jennifer, Chief Financial Officer
Hyep Ivan, Chief Financial Officer
Mazumdar Claire, Chief Executive Officer
Bender Jeremy, Director
Oliger Christy J., Director
RA CAPITAL MANAGEMENT, L.P., Director

How to read Form 4 transaction codes